| Literature DB >> 32769177 |
Johanna I Westbrook1, Ling Li2, Magdalena Z Raban2, Amanda Woods2, Alain K Koyama2, Melissa Therese Baysari3, Richard O Day4, Cheryl McCullagh5, Mirela Prgomet2, Virginia Mumford2, Luciano Dalla-Pozza6, Madlen Gazarian7, Peter J Gates2, Valentina Lichtner2,8, Peter Barclay9, Alan Gardo10, Mark Wiggins11, Leslie White2.
Abstract
BACKGROUND: Double-checking the administration of medications has been standard practice in paediatric hospitals around the world for decades. While the practice is widespread, evidence of its effectiveness in reducing errors or harm is scarce.Entities:
Keywords: human factors; medication safety; paediatrics
Year: 2020 PMID: 32769177 PMCID: PMC7982937 DOI: 10.1136/bmjqs-2020-011473
Source DB: PubMed Journal: BMJ Qual Saf ISSN: 2044-5415 Impact factor: 7.035
Figure 1Observer using a handheld device with Precise Observation System for the Safe Use of Medicines (POSSUM) software to record details of medications being prepared and administered to patients.
Characteristics of medication administrations by double-checking status (n=5140)
| Category and variable* | Double-checking | Double-checking | ||
| Single-checked | Double-checked | Single-checked | Double-checked | |
|
| 133 (57.6%) | 1981 (59.5%) | 770 (66.3%) | 307 (73.8%) |
|
| ||||
| Number of MAEs | 163 | 2387 | 427 | 121 |
| Mean (/100 administrations) | 71 | 72 | 37 | 29 |
| Potential harm severity† | ||||
| Minimum/minor | 67 (29%) | 974 (29.2%) | 314 (27.1%) | 78 (18.8%) |
| Moderate/serious | 31 (13.4%) | 377 (11.3%) | 77 (6.6%) | 31 (7.5%) |
|
| ||||
| Age, years (mean±SD) | 7.9±5.9 | 8.3±6.1 | 7.8±5.8 | 8.7±6.0 |
| Female gender | 125 (54.1%) | 1698 (51.0%) | 552 (47.6%) | 223 (53.6%) |
|
| ||||
| Age, years | ||||
| 18–29 | 113 (48.9%) | 1550 (46.5%) | 483 (41.6%) | 176 (42.3%) |
| 30–39 | 49 (21.2%) | 707 (21.2%) | 271 (23.3%) | 78 (18.8%) |
| 40–49 | 39 (16.9%) | 661 (19.8%) | 298 (25.7%) | 128 (30.8%) |
| 50–59 | 24 (10.4%) | 317 (9.5%) | 88 (7.6%) | 24 (5.8%) |
| ≥60 | 6 (2.6%) | 97 (2.9%) | 21 (1.8%) | 10 (2.4%) |
| Female gender | 211 (91.3%) | 3118 (93.6%) | 1085 (93.5%) | 379 (91.1%) |
| Registered nurse | 193 (83.6%) | 2987 (89.7%) | 1161 (100%) | 416 (100%) |
| Years of experience | ||||
| 0–<2 | 48 (20.8%) | 590 (17.7%) | 212 (18.3%) | 110 (26.4%) |
| 2–<5 | 60 (26.0%) | 884 (26.5%) | 252 (21.7%) | 80 (19.2%) |
| 5–<10 | 45 (19.5%) | 610 (18.3%) | 171 (14.7%) | 43 (10.3%) |
| 10–<15 | 18 (7.8%) | 324 (9.7%) | 113 (9.7%) | 31 (7.5%) |
| 15–<20 | 17 (7.4%) | 314 (9.4%) | 144 (12.4%) | 43 (10.3%) |
| 20–<25 | 28 (12.1%) | 367 (11.0%) | 189 (16.3%) | 77 (18.5%) |
| ≥25 | 15 (6.5%) | 243 (7.3%) | 80 (6.9%) | 32 (7.7%) |
|
| ||||
| On usual ward | 200 (86.6%) | 2690 (80.7%) | 1035 (89.2%) | 369 (88.7%) |
| Time of day | ||||
| 07:00–<10:00 | 80 (34.6%) | 1006 (30.2%) | 504 (43.4%) | 175 (42.1%) |
| 10:00–<14:00 | 52 (22.5%) | 734 (22.0%) | 282 (24.3%) | 104 (25.0%) |
| 14:00–<18:00 | 29 (12.6%) | 521 (15.6%) | 138 (11.9%) | 30 (7.2%) |
| 18:00–<22:00 | 70 (30.3%) | 1071 (32.1%) | 237 (20.4%) | 107 (25.7%) |
| Weekday | 197 (85.3%) | 2632 (79.0%) | 954 (82.1%) | 334 (80.3%) |
| eMM present on ward | 153 (66.2%) | 2042 (61.3%) | 645 (55.6%) | 173 (41.6%) |
| No. of interruptions | ||||
| 0 | 136 (58.9%) | 2031 (61.0%) | 846 (72.9%) | 302 (72.6%) |
| 1 | 57 (24.7%) | 785 (23.6%) | 219 (18.9%) | 82 (19.7%) |
| 2 | 23 (10.0%) | 296 (8.9%) | 62 (5.3%) | 23 (5.5%) |
| ≥3 | 15 (6.5%) | 220 (6.6%) | 34 (2.9%) | 9 (2.2%) |
| No. of multitasks | ||||
| 0 | 175 (75.8%) | 2692 (80.8%) | 931 (80.2%) | 369 (88.7%) |
| 1 | 37 (16.0%) | 429 (12.9%) | 168 (14.5%) | 38 (9.1%) |
| ≥2 | 19 (8.2%) | 211 (6.3%) | 62 (5.3%) | 9 (2.2%) |
| Parent at bedside | 202 (87.5%) | 2975 (89.3%) | 1062 (91.5%) | 374 (89.9%) |
| Administration route | ||||
| Oral | 156 (67.5%) | 2202 (66.1%) | 997 (85.9%) | 337 (81.0%) |
| Inhalation | 10 (4.3%) | 54 (1.6%) | 77 (6.6%) | 36 (8.7%) |
| IV infusion | 43 (18.6%) | 752 (22.6%) | 0 (0.0%) | 0 (0.0%) |
| IV injection | 17 (7.4%) | 226 (6.8%) | 0 (0.0%) | 0 (0.0%) |
| Other‡ | 5 (2.2%) | 98 (2.9%) | 87 (7.5%) | 43 (10.3%) |
*Counts and proportions are shown for all variables unless defined otherwise.
†Each administration could have multiple errors. All MAEs were considered together for potential harm severity rating. Hence the totals of MAE and severity ratings will differ.
‡Other includes ear, eye, nasal, rectal, subcutaneous injection, topical, transdermal, intramuscular injection.
eMM, electronic medication management system; MAE, medication administration error.
ORs of the association between double-checking and any MAEs and potential MAE severity*
| Outcome of interest | Double-checking mandatory | Double-checking optional | ||
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Any MAEs | 0.89 (0.65 to 1.21) | 0.44 | 0.71 (0.54 to 0.95) | 0.02 |
| Potential severity | 0.86 (0.65 to 1.15) | 0.31 | 0.75 (0.57 to 0.99) | 0.04 |
*The results presented are derived from generalised linear mixed effect models (for details see Statistical analysis section).
MAE, medication administration error.
Figure 2Flowchart of study results.
Factors associated with adherence to mandatory double-checking (n=3563 administrations)
| Related factors | OR of double-checking (95% CI) | P value |
|
| 0.03 | |
| A | Ref. | |
| B | 1.37 (0.8 to 2.35) | |
| C | 1.23 (0.76 to 1.97) | |
| D | 1.52 (0.9 to 2.57) | |
| E | 0.78 (0.48 to 1.24) | |
| F | 0.71 (0.37 to 1.35) | |
| G | 2.1 (1.08 to 4.11) | |
| H | 1.18 (0.65 to 2.12) | |
| I | 1.58 (0.89 to 2.80) | |
|
| 1.58 (1.07 to 2.32) | 0.02 |
|
| 0.72 (0.53 to 0.98) | 0.03 |
|
| 1.50 (1.02 to 2.21) | 0.04 |
eMM, electronic medication management.
Factors associated with the use of optional double-checking (n=1577 administrations)
| Related factors | OR of double-checking (95% CI) | P value |
|
| <0.0001 | |
| A | Ref. | |
| B | 0.58 (0.37 to 0.91) | |
| C | 0.9 (0.51 to 1.59) | |
| D | 0.7 (0.38 to 1.26) | |
| E | 0.31 (0.18 to 0.52) | |
| F | 0.33 (0.21 to 0.52) | |
| G | 0.49 (0.30 to 0.80) | |
| H | 0.34 (0.18 to 0.64) | |
| I | 1.94 (0.93 to 4.04) | |
|
| 0.0005 | |
| 0–2 | Ref. | |
| 2–5 | 0.52 (0.36 to 0.75) | |
| 5–10 | 0.38 (0.25 to 0.59) | |
| 10–15 | 0.56 (0.34 to 0.90) | |
| 15–20 | 0.61 (0.39 to 0.95) | |
| 20–25 | 0.65 (0.45 to 0.95) | |
| ≥25 | 0.79 (0.48 to 1.31) | |
|
| 0.03 | |
| 0 | Ref. | |
| 1 | 0.68 (0.46 to 0.99) | |
| ≥2 | 0.49 (0.24 to 1.02) | |
| | 0.48 (0.37 to 0.62) | <0.0001 |
| | 0.02 | |
| Oral | Ref. | |
| Inhalation | 1.28 (0.80 to 2.04) | |
| Other† | 1.76 (1.15 to 2.67) | |
| | 0.01 | |
| 07:00–<10:00 | Ref. | |
| 10:00–<14:00 | 1.23 (0.88 to 1.71) | |
| 14:00–<18:00 | 0.80 (0.50 to 1.29) | |
| 18:00–<22:00 | 1.57 (1.13 to 2.18) |
*All IV and IV injection administrations required double-checking.
†Other includes ear, eye, nasal, rectal, subcutaneous injection, topical, transdermal, intramuscular injection.
eMM, electronic medication management.